Clinical Trials Browser

dostarlimab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06567782 2026-03-12

AZUR-4

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT05819892 2026-03-11

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT06830239 2026-02-12

Superhero

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT07408063 2026-02-12

BeeHive

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Recruiting

Brain Neoplasms

NCT04774419 2026-02-03

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Phase 2 Recruiting

Endometrial Neoplasms

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07381777 2026-02-02

IMMUNOSTAR

Phase 2 Not yet recruiting

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

Neoplasms, Neuroblastoma, Osteosarcoma

NCT06879717 2026-01-16

PULMO-01

Phase 1/2 Active not recruiting

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT07336147 2026-01-14

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT06238635 2026-01-13

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06062420 2026-01-09

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03843359 2026-01-08

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

97 enrolled 45 charts

Bites and Stings, Neoplasms

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05723562 2026-01-08

AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03955978 2026-01-06

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT05277051 2025-12-19

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Phase 2 Active not recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07269249 2025-12-08

RW-NEDOS

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2 Recruiting

Penile Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

Phase 2 Recruiting

EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06640049 2025-11-17

China AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1/2 Active not recruiting

CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT04126200 2025-11-06

DREAMM5

Phase 2 Active not recruiting

Multiple Myeloma

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Phase 2 Active not recruiting

Melanoma

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT04655976 2025-09-26

COSTAR Lung

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06256588 2025-09-25

JADE

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT07115927 2025-08-19

RODEO

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms